BioNTech, known for its coronavirus vaccine, has announced significant changes that include both a strategic realignment and job cuts. Due to an expected high net loss in 2024, BioNTech plans to cut up to 1,350 full-time positions by the end of 2027.

At the same time, BioNTech is pursuing a strategic realignment toward oncology. The company is investing heavily in the development of mRNA cancer therapies and expects to receive its first market approvals by 2026. To support this transformation, BioNTech plans to create up to 1,200 new jobs, primarily at its headquarters in Mainz.

BioNTech relies on the support of Seitz's team specializing in large-scale employment and labor law projects, led by partners Dr. Stefan Seitz (Cologne) and Dr. Stefan Lochner (Munich), to implement employment and labor law measures within the group.